[Featured Stock] Helixmith Rises on Anticipation of Interim Results from Enzensys Phase 3-2 Clinical Trial
[Asia Economy Reporter Jang Hyowon] Helixmith is showing strong performance. This is interpreted as being driven by expectations that interim results of the Phase 3-2 clinical trial for the gene therapy 'Engensis (VM202)' will be announced in July.
As of 10:02 AM on the 24th, Helixmith is trading at 25,500 KRW, up 3.45% compared to the previous day.
On the 15th, Helixmith CEO Kim Sun-young stated at the '2022 BIO International Convention (BIO USA)' held in California, USA, that interim results of the Phase 3-2 trial for Engensis are expected to be released around mid-July.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Jeong Yu-kyung Is a Neighbor"...Itaewon Standalone House with Record 23.2 Billion Won Appraisal Up for Auction [Real Estate AtoZ]
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Engensis is one of Helixmith's core pipelines. Currently, the Phase 3-2 clinical trial for diabetic peripheral neuropathy (DPN) is underway. In July, the independent data monitoring committee (IDMC) of the U.S. Food and Drug Administration (FDA) will decide whether to 'continue the trial,' 'modify the trial design,' or 'terminate the trial,' and will recommend this to the trial sponsor. CEO Kim mentioned that unless a recommendation to terminate the trial is made, the success probability of the Phase 3-2 trial can be considered high.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
